Biochemical evaluation of the application of ischemic remote preconditioning in patients with breast cancer in chemotherapeutic treatment containing anthracyclines.

Faculdade de Medicina do ABC (FMABC)0 个研究点开始时间: 2017年11月24日最近更新: 2023年5月29日

适应症

试验速览

暂无简介。

•Sign the informed consent form prior to any study procedure; histologically proven breast cancer for chemotherapy with anthracyclics for neoadjuvant or adjuvant treatment; women; older than 18 years; Estimated life expectancy over six months.

•Uncontrolled active infection with significant clinical impairment of ventricular ejection fraction (LVEF assessed by echocardiogram should be above the lower limit of normal
•respective study center); severe cardiac valvulopathy; myocardial infarction; unstable angina pectoris; uncontrolled hypertension or uncontrolled arrhythmias up to six months prior to admission to the study; anterior or concomitant chemotherapy for previous treatment of breast cancer; bilateral mastectomy; active and known drug dependence, including alcoholism; history of positivity for the hepatitis B surface antigen, hepatitis C virus or HIV; woman in breastfeeding phase; a woman of childbearing age who is not consenting to the effective
•Birth control methods (eg, sterilization, withdrawal, birth control pills, Depo-Provera injections or
•contraceptive implants) during treatment; not be available to complete all necessary procedures for study visits; history or evidence of any clinically significant condition or other disorder or illness that may hinder the evaluation of procedures.

发起方

Faculdade de Medicina do ABC (FMABC)